REVIEW article
Front. Immunol.
Sec. Mucosal Immunity
This article is part of the Research TopicInnovations in targeting intestinal immunity for chronic inflammatory disordersView all 11 articles
Annexin A1 and A2 in Inflammatory Bowel Disease Pathogenesis: Exploring New Avenues for Diagnosis and Treatment
Provisionally accepted
Najib Muaamer Faed Murshed1*
Praveenkumar Shetty2Pavan K. Jayaswamy3Ankeeta Menona Jacob4Samah Saleh Ahmed Alawadhi3Kishan Prasad H L1*- 1Department of Pathology, K S Hegde Medical Academy, Mangalore, India
- 2Department of Biochemistry / Central Research Laboratory, K S Hegde Medical Academy, Mangalore, India
- 3Central Research Laboratory, K S Hegde Medical Academy, Mangalore, India
- 4Department of Community Medicine, K S Hegde Medical Academy, Mangalore, India
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a significant global health burden with gastrointestinal inflammation resulting from dysfunctional immune responses and chronic inflammation. This review synthesizes the roles of annexin A1 (AnxA1) and annexin A2 (AnxA2) in the pathophysiology of IBD, their diagnostic biomarkers, and therapeutic potential. AnxA1 interacts with FPR2/ALX receptors, inhibiting the release of pro-inflammatory cytokines and promoting epithelial cell repair. AnxA2 exhibits dual roles by interacting with S100A10. AnxA2 can induce NF-κB activation, promoting pro-inflammatory cytokine release and plasminogen activation. On the other hand, AnxA2 activates the TRAM-TRIF pathway, inhibiting NF-κB activation, promoting production of anti-inflammatory cytokines, fibrinolysis, and restoring tight junctions. Their modulation of NF-κB pathways shapes the molecular landscape of IBD. AnxA1 and AnxA2 are non-invasive plasma biomarkers that improve subtype-specific diagnostic accuracy compared to C-reactive protein. In the therapeutic context, AnxA1 mimetics and AnxA2 inhibitors reduce inflammation and promote healing, potentially in conjunction with anti-TNF drugs or nanoparticle delivery. Longitudinal studies and clinical trials are essential to identify the gaps in the standardization of testing and cytokine network interactions. AnxA1 and AnxA2 have the potential to transform the development of precise diagnostics and personalized therapies, redefining the management of IBD.
Keywords: inflammatory bowel disease, Annexin A1, Annexin A2, biomarker, And pathogenesis
Received: 15 Oct 2025; Accepted: 03 Dec 2025.
Copyright: © 2025 Murshed, Shetty, Jayaswamy, Jacob, Alawadhi and L. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Najib Muaamer Faed Murshed
Kishan Prasad H L
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.